ArticleEuropean radiology experimental2025
Deep learning for automated segmentation of central cartilage tumors on MRI.
Article in European radiology experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Peer review: historical evolution and reviewers' learning.Insights into imaging · 2026Review
- Development and validation of a multiparametric MRI-based radiomics nomogram for the tripartite discrimination of primary benign, primary malignant, and metastatic lumbar spinal tumors.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAutomated segmentation methods may potentially increase the reliability and applicability of radiomics in skeletal oncology. Our aim was to propose a deep learning-based method for automated segmentation of atypical cartilaginous tumor (ACT) and grade II chondrosarcoma (CS2) of long bones on magnetic resonance imaging (MRI). MATERIALS AND
methodsThis institutional review board-approved retrospective study included 164 patients with surgically treated and histology-proven cartilaginous tumors at two tertiary bone tumor centers. The first cohort consisted of 99 MRI scans from center 1 (79 ACT, 20 CS2). The second cohort consisted of 65 MRI scans from center 2 (45 ACT, 20 CS2). Supervised Edge-Attention Guidance segmentation Network (SEAGNET) architecture was employed for automated image segmentation on T1-weighted images, using manual segmentations drawn by musculoskeletal radiologists as the ground truth. In the first cohort, a total of 1,037 slices containing the tumor out of 99 patients were split into 70% training, 15% validation, and 15% internal test sets, respectively, and used for model tuning. The second cohort was used for independent external testing.
resultsIn the first cohort, Dice Score (DS) and Intersection over Union (IoU) per patient were 0.782 ± 0.148 and 0.663 ± 0.175, and 0.748 ± 0.191 and 0.630 ± 0.210 in the validation and internal test sets, respectively. DS and IoU per slice were 0.742 ± 0.273 and 0.646 ± 0.266, and 0.752 ± 0.256 and 0.656 ± 0.261 in the validation and internal test sets, respectively. In the independent external test dataset, the model achieved DS of 0.828 ± 0.175 and IoU of 0.706 ± 0.180.
conclusionDeep learning proved excellent for automated segmentation of central cartilage tumors on MRI. RELEVANCE STATEMENT: A deep learning model based on SEAGNET architecture achieved excellent performance for automated segmentation of cartilage tumors of long bones on MRI and may be beneficial, given the increasing detection rate of these lesions in clinical practice. KEY POINTS: Automated segmentation may potentially increase the reliability and applicability of radiomics-based models. A deep learning architecture was proposed for automated segmentation of appendicular cartilage tumors on MRI. Deep learning proved excellent with a mean Dice Score of 0.828 in the external test cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.